Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma

Table 5 Prognostic factors for PIVKA II response n (%)

Prognostic factors	Univariate analysis			Multivariate analysis
	PIVKA II		P value	Odds ratio	95%CI	P value
	Decrease	Increase
Gender			0.278
Female	3 (33)	6 (67)
Male	25 (57)	19 (43)
Age (yr)			0.052
< 70	12 (40)	18 (60)
≥ 70	16 (70)	7 (30)		0.359	0.093-1.390	0.139
AFP (ng/mL)			0.738
< 400	18 (55)	15 (45)
≥ 400	10 (50)	10 (50)
BCLC			0.404
Advanced	26 (55)	21 (45)
Terminal	2 (33)	4 (67)
Child-Pugh			0.267
< 7	20 (59)	14 (41)
≥ 7	8 (42)	11 (58)
Diameter (mm)			0.056
< 30	10 (38)	16 (62)
≥ 30	18 (67)	9 (33)		0.185	0.047-0.730	0.016
Dose (Gy)			< 0.001
< 30	15 (38)	24 (62)
≥ 30	13 (93)	1 (7)		0.270	0.021-3.40	0.312
Dose/Fraction (Gy)			0.769
< 8	8 (47)	9 (53)
≥ 8	20 (56)	16 (44)
Lesion			0.026
Intrahepatic	8 (89)	1 (11)
Extrahepatic	20 (45)	24 (55)		0.000	0.00-∞	0.994
Fiducial			0.001
(-)	16 (40)	24 (60)
(+)	12 (92)	1 (8)		0.035	0.003-0.342	0.004
Sorafenib			1.000
(-)	22 (52)	20 (48)
(+)	6 (55)	5 (45)

Fisher's exact test and a logistic regression model were used to evaluate prognostic factors for PIVKA II response.